research Janus kinase inhibition for the treatment of refractory frontal fibrosing alopecia: A case series and review of the literature
JAK inhibitors, like ruxolitinib, may effectively treat frontal fibrosing alopecia.
Search
for
Sort by
Research
630-660 / 1000+ resultsresearch Clinical and hormonal effects of the 5 alpha-reductase inhibitor finasteride in idiopathic hirsutism
research Control of testosterone 5alpha-reductase activity in the human hyperplastic prostate
Inhibiting testosterone 5alpha-reductase may help treat benign prostatic hyperplasia.
research 5ARI and PSA: open questions
5ARI treatment improves PSA test accuracy for prostate cancer diagnosis.
research Host-Directed FDA-Approved Drugs with Antiviral Activity against SARS-CoV-2 Identified by Hierarchical In Silico/In Vitro Screening Methods
Five FDA-approved drugs may help block COVID-19 virus entry.
research 124 The Persistent Effects of 5α-reductase Inhibitors Used in the Treatment of Androgenic Alopecia on Men’s Health
Using 5α-reductase inhibitors for hair loss can cause lasting sexual, physical, mental, and vascular health issues in men, even after stopping the medication.
research Cloning, computational analysis and expression profiling of steroid 5 alpha-reductase 1 (SRD5A1) gene during reproductive phases and ovatide stimulation in endangered catfish, Clarias magur
The research identified and described a gene important for hormone conversion in endangered catfish, which varies in activity during different reproductive stages and after hormone treatment.
research Synthesis of 5α-Reductase Special inhibitor Finasteride
Finasteride is made through a series of chemical reactions starting from a specific intermediate compound.
research Evaluating the safety profile of α-1 blockers, 5α-reductase inhibitors, and PDE5I for BPH: a disproportionality analysis of real-world adverse events based on FDA adverse event reporting system (FAERS)
These medications for BPH have known risks and may have new side effects.
research A Promising Efficacy of Tofacitinib in an Adult Patient with Alopecia Areata
Tofacitinib effectively treated severe hair loss in a patient who didn't respond to other treatments.
research Determination Method for Steroid 5α-Reductase Activity Using Liquid Chromatography/Atmospheric Pressure Chemical Ionization–Mass Spectrometry
A new method was developed to measure and assess the activity and inhibition of the enzyme steroid 5α-reductase.
research Ranitidine and finasteride inhibit the synthesis and release of trimethylamine N-oxide and mitigates its cardiovascular and renal damage through modulating gut microbiota
Ranitidine and finasteride lower TMAO levels, reducing heart and kidney damage by changing gut bacteria.
research Safety Assessment of Ritlecitinib Based on the FDA Adverse Event Reporting System (FAERS ) Database: A Real‐World Pharmacovigilance Study
Ritlecitinib has common side effects like headache and acne, and unexpected ones like diabetes and thyroid issues.
research Do 5α-Reductase Inhibitors Raise Circulating Serum Testosterone Levels? A Comprehensive Review and Meta-Analysis to Explaining Paradoxical Results
5α-Reductase inhibitors do not consistently increase testosterone levels in the blood.
research Differential expression of steroid 5α-reductase isozymes and association with disease severity and angiogenic genes predict their biological role in prostate cancer
SRD5A1 is crucial in advanced prostate cancer, and blocking both SRD5A1 and SRD5A2 is more effective than targeting SRD5A2 alone.
research The Impact of 5α-Reductase Inhibitor Use for Male Pattern Hair Loss on Men’s Health
Hair loss drugs may cause sexual issues and infertility in men.
research The antiviral activity of a small molecule drug targeting the NSP1-ribosome complex against Omicron, especially in elderly patients
Golvatinib shows promise as a treatment for Omicron in elderly patients.
research The 5α-reductase inhibitor finasteride reduces opioid self-administration
Finasteride may help reduce opioid use.
research Sexual dysfunction with 5-alpha-reductase inhibitor therapy for androgenetic alopecia: a global propensity score matched retrospective cohort study
Taking medication for hair loss might cause sexual problems.
research 5α-Reductase Inhibitors Do Not Prevent the Development and Progression of Urothelial Cancer: In Vitro Evidence
5α-reductase inhibitors don't stop bladder cancer from developing or getting worse.
research In silico screening of effective inhibitor of 5α-reductase type 1 for androgenic alopecia treatment
β-sitosterol and brassicasterol may help treat hair loss.
research Considerations for the Treatment Strategy of Relapse After Tofacitinib Therapy in Alopecia Areata
Alternative treatments are needed when Tofacitinib alone fails for alopecia areata.
research Study on inhibitory effect of Urtica laetevirens Maxim. extract on 5α-reductase
Urtica laetevirens extract significantly reduces 5α-reductase activity.
research Systematic review and indirect treatment comparisons of ritlecitinib against baricitinib in alopecia areata
Ritlecitinib and baricitinib are similarly effective for hair regrowth in severe alopecia areata.
research Efficacy and Safety of Switching from Baricitinib to Ritlecitinib in Severe Alopecia Areata
Switching to ritlecitinib improves hair regrowth and well-being in severe alopecia areata patients.
research A rapid method for obtaining finasteride, a 5α-reductase inhibitor, from commercial tablets
Quickly get finasteride from tablets using easy methods.
research Correction to: An evaluation of the federal adverse events reporting system data on adverse effects of 5‑alpha reductase inhibitors
The correction states that the label change for Finasteride was in 2012, leading to more reports of side effects from non-healthcare people.
research A Case of Tofacitinib for the Treatment of Resistant Vitiligo and Sustained Repigmentation After Discontinuation
A woman's vitiligo improved with tofacitinib treatment, and her skin color remained even after stopping the medication, but there are concerns about cancer risk.
research Comprehensive Safety Exposure‐Response Analysis to Support Ritlecitinib Dose Selection
A 50 mg non-loading dose of ritlecitinib is safe for adults and adolescents.
research Adverse events in patients treated with Jak‐inhibitors for alopecia areata: A systematic review
JAK-inhibitors for alopecia areata are generally safe with mostly mild side effects and a low rate of treatment withdrawal.